OREANDA-NEWS. On June 21, 2007 OAO Pharmacy Chain 36.6 [MICEX:RU14APTK1007; RTS:APTK] announced 2006 financial results (audited by Deloitte) in accordance with the International Financial Reporting Standards (IFRS), reported the press-centre of OAO Pharmacy Chain 36.6.

Sales

Consolidated sales grew 73% y-o-y in 2006 and reached $528,9 million.

Sales in the pharmacy segment increased by 90% and reached $386,2 million in 2006.  This growth was facilitated in part by the opening of 75 new pharmacies and acquisition of 18 regional pharmacy chains consisting of 352 pharmacies. Sales at pharmacies that had been operating for more than one year (like-for-like) at the end of 2006 grew by 25,5%.

PRO-FORMA pharmacy segment sales (sales including non-consolidated retail revenues in 2006) grew by 141% and amounted to $489,6 million.

Veropharm sales reached $100,5 million, up 27% y-o-y. This increase was primarily due to a significant growth in sales of the prescription drugs portfolio.

Sales of European Medical Center reached $20,5 million of which $10,5 were consolidated into IFRS report.

Profit

Consolidated gross profit grew 56% in 2006 and reached $183,4 million. Active development of the regional drugstore network led to a gross margin decline from 33,1% to 29,1% in the retail segment.

The Company’s consolidated EBITDA grew by 9%, reaching $25,5 million.  EBITDA in the production sector was up 17% and amounted to $29,2 million. Retail EBITDA was down at $ -1,2 million, while PRO-FORMA retail EBITDA amounted to $3,7 million.

Profit in 2006 totaled $34,5 million. This increase in net profit was due to the Veropharm`s IPO in April of 2006.

Investment and Other Indicators

In 2006, Pharmacy Chain 36.6 invested $164,1 million in opening new pharmacies, re-branding and acquisition of regional pharmacy chains, as well as on real estate acquisitions and in production and medical services.

In 2006, the Company’s financial debt as of the end of 2006 reached $253,1 million.